课题基金 / 基金详情

PHASE I TRIAL OF BL 1001 AS 6 HOUR INFUSION

PHASE I TRIAL OF BL 1001 AS 6 HOUR INFUSION
BL 1001 6 小时输注的 I 期试验
批准号：
6120098
负责人：
S. Gail Eckhardt
金额：
$1.64万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6120098
关键词：
antineoplastics clinical research clinical trial phase I dosage drug screening /evaluation human subject human therapy evaluation injection /infusion neoplasm /cancer chemotherapy pharmacokinetics

项目摘要

项目成果

S. Gail Eckhardt的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The primary objective of this study is to determine the maximum tolerated dose of BL-1001 administered as a six-hour daily infusion for five days every 21 days to patients with advanced cancer. The secondary objectives include determining the qualitative and quantitative toxicities of BL-1001, determining the recommended dose to be used in therapeutic trials, determining the basic pharmacokinetics of BL-1001, and collecting information about the antitumor effects of BL-1001.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Southwest Early Clinical Trials Consortium
Southwest Early Clinical Trials Consortium
Southwest Early Clinical Trials Consortium
Southwest Early Clinical Trials Consortium
海外基金